Teva Catapults 22%, Hitting A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.
Advertisement
- My Portfolio
- News
- Markets
- Stocks: Most Actives
- Stocks: Gainers
- Stocks: Losers
- Trending Tickers
- Futures
- World Indices
- US Treasury Bonds Rates
- Currencies
- Crypto
- Top ETFs
- Top Mutual Funds
- Options: Highest Open Interest
- Options: Highest Implied Volatility
- Sectors
- Basic Materials
- Communication Services
- Consumer Cyclical
- Consumer Defensive
- Energy
- Financial Services
- Healthcare
- Industrials
- Real Estate
- Technology
- Utilities
- Research
- Personal Finance
- Videos
- Streaming Now
New on Yahoo
New on Yahoo
© 2024 All rights reserved.
Yahoo Finance
Yahoo FinanceSome parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.